Validation of genomic and transcriptomic models of homologous recombination deficiency in a real-world pan-cancer cohort

Abstract excerpt

BACKGROUND: With the introduction of DNA-damaging therapies into standard of care cancer treatment, there is a growing need for predictive diagnostics assessing homologous recombination deficiency (HRD) status across tumor types. Following the strong clinical evidence for the utility of DNA-sequencing-based HRD testing in ovarian cancer, and growing evidence in breast cancer, we present analytical validation of...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to BRCA gene mutations in cancer
• Share to DNA Repair Mechanisms
• Share to PARP inhibition in cancer therapy